Loading...
•
Sep 30, 2022
Trevena Q3 2022 Earnings Report
Trevena reported results for the third quarter of 2022, including a net loss of $15.3 million and a cash balance of $40.4 million. OLINVYK commercialization progressed with Vizient contract and receipt of CMS outpatient pass-through reimbursement. Positive Phase 1 topline results were reported for TRV045.
Key Takeaways
Trevena reported a net loss of $15.3 million for Q3 2022. The company's cash balance was $40.4 million as of September 30, 2022, expected to fund operations into Q3 2023. OLINVYK commercialization progressed and positive Phase 1 data was reported for TRV045.
OLINVYK received CMS pass-through reimbursement for ambulatory surgical centers and hospital outpatient settings.
Relationship with Vizient is advancing, enabling efficient resource management.
Positive topline Phase 1 data was reported for TRV045, a novel S1P receptor modulator.
Targeted TRV045 proof-of-concept study to assess CNS activity is planned for early 2023.
Forward Guidance
Trevena expects its cash balance of $40.4 million as of September 30, 2022, will be sufficient to fund the Company’s operating expenses and capital expenditure requirements into the third quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...